RS62220B1 - Oksisteroli i postupci njihovog korišćenja - Google Patents

Oksisteroli i postupci njihovog korišćenja

Info

Publication number: RS62220B1
Authority: RS; Serbia
Prior art keywords: compound; formula; mmol; disorder; mixture
Prior art date: 2015-07-06

Application number

RS20211000A

Other languages

English (en)

Serbian (sr)

Inventor

Francesco G Salituro

Albert Jean Robichaud

Botella Gabriel Martinez

Boyd L Harrison

Original Assignee

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-07-06

Publication date

2021-09-30

2016-07-06 Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc

2021-09-30 Publication of RS62220B1 publication Critical patent/RS62220B1/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

RS20211000A 2015-07-06 2016-07-06 Oksisteroli i postupci njihovog korišćenja RS62220B1 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562189068P	2015-07-06	2015-07-06
US201662332931P	2016-05-06	2016-05-06
PCT/US2016/041175 WO2017007840A1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof
EP16821926.9A EP3319612B1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof

Publications (1)

Publication Number	Publication Date
RS62220B1 true RS62220B1 (sr)	2021-09-30

Family

ID=57686127

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20211000A RS62220B1 (sr)	2015-07-06	2016-07-06	Oksisteroli i postupci njihovog korišćenja
RS20250662A RS66996B1 (sr)	2015-07-06	2016-07-06	Oksisteroli i postupci njihove upotrebe

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20250662A RS66996B1 (sr)	2015-07-06	2016-07-06	Oksisteroli i postupci njihove upotrebe

Country Status (30)

Country	Link
US (3)	US11117924B2 (2)
EP (3)	EP4599887A3 (2)
JP (4)	JP2018519328A (2)
KR (2)	KR20240166589A (2)
CN (3)	CN118994288A (2)
AU (3)	AU2016289971C1 (2)
CA (1)	CA2991313C (2)
CO (1)	CO2018000589A2 (2)
CY (1)	CY1124620T1 (2)
DK (2)	DK3319612T3 (2)
ES (2)	ES3036110T3 (2)
FI (1)	FI3812392T3 (2)
HR (2)	HRP20211282T1 (2)
HU (2)	HUE071964T2 (2)
IL (3)	IL289976B2 (2)
LT (2)	LT3319612T (2)
MA (1)	MA54851A (2)
MD (1)	MD3319612T2 (2)
MX (3)	MX390271B (2)
MY (1)	MY197698A (2)
PE (1)	PE20180482A1 (2)
PH (2)	PH12020551586A1 (2)
PL (2)	PL3319612T3 (2)
PT (2)	PT3812392T (2)
RS (2)	RS62220B1 (2)
RU (1)	RU2742333C2 (2)
SG (1)	SG10202002655VA (2)
SI (2)	SI3812392T1 (2)
SM (2)	SMT202100476T1 (2)
WO (1)	WO2017007840A1 (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2848212C (en)	2011-09-08	2022-03-29	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt)	2013-03-13	2018-12-05	Sage Therapeutics Inc	Esteroides neuroativos e métodos para o seu uso
US10259840B2 (en)	2014-06-18	2019-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
HUE071964T2 (hu) *	2015-07-06	2025-10-28	Sage Therapeutics Inc	Oxiszterolok és alkalmazási eljárásaik
CA2991311C (en)	2015-07-06	2025-05-06	Sage Therapeutics, Inc.	OXYSTEROLS AND THEIR METHODS OF USE
EP3828194B1 (en)	2015-07-06	2025-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
SMT202200300T1 (it)	2016-04-01	2022-09-14	Sage Therapeutics Inc	Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en)	2016-05-06	2017-11-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es)	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
KR20230051723A (ko)	2016-10-18	2023-04-18	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
RU2019115113A (ru)	2016-10-18	2020-11-24	Сейдж Терапьютикс, Инк.	Оксистеролы и способы их применения
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN113121631B (zh) *	2021-03-25	2023-02-03	西北农林科技大学	一种羊毛甾烷灵芝三萜类化合物、制备方法及应用
IL309208A (en)	2021-06-11	2024-02-01	Sage Therapeutics Inc	Neuroactive steroid for the treatment of alzheimer's disease
WO2023114224A1 (en)	2021-12-13	2023-06-22	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025020191A1 (zh) *	2023-07-27	2025-01-30	珂阑(上海)医药科技有限公司	甾类化合物、其制备方法和应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2259698A (en)	1938-05-07	1941-10-21	Rare Chemicals Inc	Physiologically effective substance and process of preparing same
US2594323A (en)	1948-07-22	1952-04-29	Upjohn Co	24-substituted delta 5-cholene-3, 24-diols
US2673206A (en)	1950-06-07	1954-03-23	Schering Corp	25-ethinyl steroids
US3079385A (en)	1961-01-24	1963-02-26	Roussel Uclaf	Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
JPS5324071B2 (2)	1974-04-30	1978-07-18
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en)	1975-10-10	1982-03-31	Hoffmann La Roche	Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja)	1976-12-28	1983-09-08	帝人株式会社	ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en)	1977-07-18	1980-01-15	Kaiser Emil T	Process for preparing 25-hydroxycholesterol
JPS54163565A (en)	1978-06-09	1979-12-26	Teijin Ltd	24255epoxyy3beta 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en)	1978-08-01	1979-11-13	Kaiser Emil T	Synthesis of steroids
US4269777A (en)	1979-05-21	1981-05-26	Wisconsin Alumni Research Foundation	Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en)	1980-08-13	1982-02-26	Teijin Ltd	25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja)	1985-05-07	1986-11-12	Sumitomo Pharmaceut Co Ltd	コレステロ−ルのフツ素誘導体
DE3664909D1 (en)	1985-05-30	1989-09-14	Taisho Pharmaceutical Co Ltd	Vitamin d3 derivatives
JPS62187485A (ja)	1986-02-13	1987-08-15	Teijin Ltd	２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69435286D1 (de)	1993-05-24	2010-05-20	Purdue Pharma Ltd	Verfahren und zusammensetzungen zum hervorrufen von schlaf
IL110309A0 (en)	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
ES2296594T3 (es)	1994-02-14	2008-05-01	Euro-Celtique S.A.	Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
IL112778A0 (en)	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5595996A (en)	1994-10-25	1997-01-21	Merck & Co., Inc.	7-substituted 4-aza cholanic acid derivatives and their use
NZ298567A (en)	1994-11-23	2000-01-28	Cocensys Inc	Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
JPH08268917A (ja)	1995-03-31	1996-10-15	D D S Kenkyusho:Kk	癌組織への移行性の高い制癌剤
US6780853B1 (en) *	1995-06-06	2004-08-24	Euro-Celtique S.A.	Neuroactive steroids of the androstane and pregnane series
ATE284895T1 (de)	1995-06-06	2005-01-15	Euro Celtique Sa	Neuroaktive steroide der androstan- und pregnanreihe
US5792635A (en)	1995-06-07	1998-08-11	Magainin Pharmaceuticals, Inc.	Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6645953B2 (en)	1995-06-23	2003-11-11	Novo Nordisk A/S	Meiosis regulating compounds
CA2224866A1 (en)	1995-06-23	1997-01-09	Novo Nordisk A/S	Meiosis regulating compounds
EP0840612A1 (en)	1995-07-24	1998-05-13	Trustees Of Boston University	Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en)	1995-07-26	1999-03-30	Trustees Of Boston University	Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997042215A1 (en)	1996-05-06	1997-11-13	Bionumerik Pharmaceuticals, Inc.	Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja)	1996-06-10	1997-12-22	Teijin Ltd	２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en)	1996-08-01	1998-02-12	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6122371A (en)	1997-07-22	2000-09-19	Atwell; Ronald C.	Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en)	1998-05-11	1999-11-18	Novo Nordisk A/S	Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko)	1998-05-13	2001-05-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	감수분열 조절 화합물
US8541600B2 (en)	1998-11-24	2013-09-24	Harbor Therapeutics, Inc.	11-aza, 11-thia and 11-oxa sterol compounds and compositions
US6376530B1 (en) *	1999-05-10	2002-04-23	Merck & Co., Inc.	Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en)	1999-05-11	1999-07-14	Res Inst Medicine Chem	Chemical compounds
CN1111167C (zh)	1999-10-22	2003-06-11	中国科学院上海有机化学研究所	3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh)	1999-11-12	2003-01-08	中国科学院上海有机化学研究所	高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en)	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
GB0019290D0 (en)	2000-08-04	2000-09-27	Symphar Sa	Methods for inducing apolipoprotein E secretion
GR1003861B (el)	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en)	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
JP4309661B2 (ja)	2001-05-03	2009-08-05	ザユニバーシティーオブシカゴ	肝臓ｘ受容体
US20070197484A1 (en)	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
WO2003039480A2 (en)	2001-11-08	2003-05-15	The University Of Chicago	Method of treating disorder related to high cholesterol concentration
WO2003049685A2 (en)	2001-12-07	2003-06-19	The Regents Of The University Of California	Treatment for age-related macular degeneration
KR20100093621A (ko)	2002-03-27	2010-08-25	파이토팜 피엘씨	사포게닌 및 그 유도체의 치료 방법 및 용도
CN102727501A (zh)	2002-03-27	2012-10-17	菲特法姆股份有限公司	皂角苷配基及其衍生物的用途
GB0216621D0 (en) *	2002-07-17	2002-08-28	Imaging Res Solutions Ltd	Imaging compounds
US6933312B2 (en)	2002-10-07	2005-08-23	Agouron Pharmaceuticals, Inc.	Pyrazole derivatives
JP2006509763A (ja) *	2002-11-22	2006-03-23	メルク　エンド　カムパニー　インコーポレーテッド	Ｎｒ２ｂ受容体アンタゴニストとしての２−［（４−ベンジル）−１−ピペリジニル）メチル］ベンゾイミダゾール−５−オール誘導体
AU2003288231A1 (en)	2002-12-13	2004-07-09	Bayer Healthcare Ag	Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr)	2003-01-17	2007-04-06	Mapreg	Medicaments pour le systeme nerveux
GB0403889D0 (en)	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
US8604011B2 (en)	2004-09-27	2013-12-10	The Regents Of The University Of California	Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en)	2004-10-08	2007-02-08	Shutsung Liao	Methods of treating cancers
JP2008518935A (ja)	2004-11-01	2008-06-05	セオホンユー	筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
CA2643732C (en)	2006-02-27	2012-08-21	The Regents Of The University Of California	Oxysterol compounds and the hedgehog pathway
CN101164540A (zh)	2006-08-03	2008-04-23	中山大学	海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en)	2006-10-06	2006-11-15	Birkeland Innovasjon As	Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en)	2006-11-02	2012-09-25	Curis, Inc.	Small organic molecule regulators of cell proliferation
DK2792681T3 (en)	2006-11-21	2017-01-23	Umecrine Ab	Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
WO2008157786A1 (en)	2007-06-20	2008-12-24	Auspex Pharmaceutical, Inc.	Substituted n-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
WO2009059961A2 (en)	2007-11-06	2009-05-14	N.V. Organon	A method of hormone suppression in humans
CN101951915A (zh)	2007-12-03	2011-01-19	加利福尼亚大学董事会	用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2009090063A1 (en)	2008-01-16	2009-07-23	Jado Technologies Gmbh	Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
AU2009206580A1 (en)	2008-01-25	2009-07-30	Merck Sharp & Dohme Corp.	Quinolizidinone M1 receptor positive allosteric modulators
KR101325374B1 (ko) *	2008-02-19	2013-11-08	가부시키가이샤 오츠까 세이야꾸 고죠	신체 기능의 회복에 유용한 경구 또는 경장 조성물
US8497122B2 (en) *	2008-04-11	2013-07-30	Washington University	Biomarkers for Niemann-pick C disease and related disorders
JP2011520815A (ja)	2008-05-09	2011-07-21	エモリー・ユニバーシテイ	精神神経障害治療のためのｎｍｄａ受容体拮抗薬
EP3656385A1 (en) *	2008-05-28	2020-05-27	ReveraGen BioPharma, Inc.	Non-hormonal steroid modulators of nf-kb for treatment of disease
WO2010065709A2 (en)	2008-12-03	2010-06-10	Amin Khan	Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en)	2008-12-22	2012-02-16	Massachusetts Institute Of Technology	Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en)	2009-01-28	2011-12-29	Emory University	Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US8829213B2 (en)	2009-07-29	2014-09-09	The University Of Chicago	Liver X receptor agonists
WO2011028794A2 (en)	2009-09-01	2011-03-10	Lazarus Therapeutics, Inc.	Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr)	2009-12-02	2015-10-16	Assist Publ Hopitaux Marseille	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
JP2011135864A (ja) *	2009-12-30	2011-07-14	Korea Univ Research & Business Foundation	Ｏｃｔ４及びＢｍｉ１、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) *	2010-05-14	2010-06-30	Ge Healthcare Ltd	Method of synthesis
US20120035156A1 (en)	2010-08-09	2012-02-09	Daniela Alberati	Combination of glyt1 compound with antipsychotics
US8969525B2 (en)	2010-11-09	2015-03-03	Enzo Life Sciences, Inc.	Hydroxycholesterol immunoassay
WO2012142039A1 (en)	2011-04-15	2012-10-18	University Of North Dakota	Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en)	2011-05-27	2012-12-06	Cytocure Llc	Methods, compositions, and kits for the treatment of cancer
JP2014521662A (ja)	2011-07-29	2014-08-28	ザリージェンツオブザユニバーシティオブカリフォルニア	ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
CA2848212C (en) *	2011-09-08	2022-03-29	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
AP2014007606A0 (en)	2011-10-07	2014-05-31	Takeda Pharmaceutical	1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EP3572417B1 (en)	2011-10-14	2025-12-17	Sage Therapeutics, LLC	3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2841067A4 (en)	2012-04-25	2016-04-13	Univ California	MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en)	2012-08-09	2014-02-13	Emory University	Nmda receptor modulators and uses related thereto
US20140149272A1 (en)	2012-08-17	2014-05-29	Trueex Group Llc	Interoffice bank offered rate financial product and implementation
CA2882870C (en) *	2012-08-24	2020-12-15	Integurx Therapeutics, Llc	Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
HUE039057T2 (hu)	2012-12-18	2018-12-28	Univ Washington	Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
EP2948152A4 (en)	2013-01-23	2016-12-14	Sphaera Pharma Private Ltd	NOVEL COMPOUNDS OF 11-BETA HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES RELATED TO MITOCHONDRIA DYSFUNCTION OR ADDITIONAL
US9758525B2 (en)	2013-01-29	2017-09-12	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
CN119269811A (zh)	2013-03-13	2025-01-07	萨奇治疗股份有限公司	神经活性类固醇、组合物、及其用途
PT2968369T (pt)	2013-03-13	2018-12-05	Sage Therapeutics Inc	Esteroides neuroativos e métodos para o seu uso
JP2016531852A (ja)	2013-09-25	2016-10-13	ヴァンアンデルリサーチインスティテュート	非常に強力なグルココルチコイド
CN103655582B (zh) *	2013-11-30	2015-05-27	浙江大学	一种环氧甾醇组合物及制备和用途
US10259840B2 (en)	2014-06-18	2019-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10238664B2 (en)	2014-07-09	2019-03-26	Duke University	Compositions and methods for the repair of myelin
US10016095B2 (en) *	2014-10-03	2018-07-10	Progressive International Corporation	Salad spinner
CA2963938C (en)	2014-10-07	2023-10-24	Sage Therapeutics, Inc.	Neuroactive compounds and methods of use thereof
HUE071964T2 (hu) *	2015-07-06	2025-10-28	Sage Therapeutics Inc	Oxiszterolok és alkalmazási eljárásaik
EP3828194B1 (en)	2015-07-06	2025-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
CA2991311C (en) *	2015-07-06	2025-05-06	Sage Therapeutics, Inc.	OXYSTEROLS AND THEIR METHODS OF USE
GB2557875A (en)	2015-09-02	2018-07-04	Univ Swansea	Diagnostic methods and kits
SMT202200300T1 (it)	2016-04-01	2022-09-14	Sage Therapeutics Inc	Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en)	2016-05-06	2017-11-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
WO2018013615A1 (en)	2016-07-11	2018-01-18	Sage Therapeutics, Inc.	C7, c12, and c16 substituted neuroactive steroids and their methods of use
ES2935057T3 (es)	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru)	2016-10-18	2020-11-24	Сейдж Терапьютикс, Инк.	Оксистеролы и способы их применения
KR20230051723A (ko)	2016-10-18	2023-04-18	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
CA3055653A1 (en)	2017-03-15	2018-09-20	Modernatx, Inc.	Lipid nanoparticle formulation
JP7224307B2 (ja)	2017-06-23	2023-02-17	インターセプトファーマシューティカルズ，インコーポレイテッド	胆汁酸誘導体の調製のための方法及び中間体
MY204493A (en)	2017-11-10	2024-08-30	Marinus Pharmaceuticals Inc	Ganaxolone for use in treating genetic epileptic disorders

2016
- 2016-07-06 HU HUE20214736A patent/HUE071964T2/hu unknown
- 2016-07-06 EP EP25170345.0A patent/EP4599887A3/en active Pending
- 2016-07-06 RS RS20211000A patent/RS62220B1/sr unknown
- 2016-07-06 JP JP2017568203A patent/JP2018519328A/ja not_active Withdrawn
- 2016-07-06 ES ES20214736T patent/ES3036110T3/es active Active
- 2016-07-06 PL PL16821926T patent/PL3319612T3/pl unknown
- 2016-07-06 SM SM20210476T patent/SMT202100476T1/it unknown
- 2016-07-06 MY MYPI2018000010A patent/MY197698A/en unknown
- 2016-07-06 FI FIEP20214736.9T patent/FI3812392T3/fi active
- 2016-07-06 CA CA2991313A patent/CA2991313C/en active Active
- 2016-07-06 RU RU2018104245A patent/RU2742333C2/ru active
- 2016-07-06 SI SI201631911T patent/SI3812392T1/sl unknown
- 2016-07-06 KR KR1020247037600A patent/KR20240166589A/ko active Pending
- 2016-07-06 US US15/742,424 patent/US11117924B2/en active Active
- 2016-07-06 MA MA054851A patent/MA54851A/fr unknown
- 2016-07-06 PH PH1/2020/551586A patent/PH12020551586A1/en unknown
- 2016-07-06 MX MX2020010690A patent/MX390271B/es unknown
- 2016-07-06 IL IL289976A patent/IL289976B2/en unknown
- 2016-07-06 EP EP20214736.9A patent/EP3812392B1/en active Active
- 2016-07-06 SG SG10202002655VA patent/SG10202002655VA/en unknown
- 2016-07-06 LT LTEP16821926.9T patent/LT3319612T/lt unknown
- 2016-07-06 SI SI201631298T patent/SI3319612T1/sl unknown
- 2016-07-06 KR KR1020187003209A patent/KR20180026742A/ko not_active Ceased
- 2016-07-06 DK DK16821926.9T patent/DK3319612T3/da active
- 2016-07-06 PT PT202147369T patent/PT3812392T/pt unknown
- 2016-07-06 EP EP16821926.9A patent/EP3319612B1/en active Active
- 2016-07-06 LT LTEP20214736.9T patent/LT3812392T/lt unknown
- 2016-07-06 CN CN202411074416.8A patent/CN118994288A/zh active Pending
- 2016-07-06 PL PL20214736.9T patent/PL3812392T3/pl unknown
- 2016-07-06 IL IL282048A patent/IL282048B2/en unknown
- 2016-07-06 WO PCT/US2016/041175 patent/WO2017007840A1/en not_active Ceased
- 2016-07-06 HU HUE16821926A patent/HUE055199T2/hu unknown
- 2016-07-06 MX MX2021005052A patent/MX2021005052A/es unknown
- 2016-07-06 PE PE2018000037A patent/PE20180482A1/es unknown
- 2016-07-06 MD MDE20180513T patent/MD3319612T2/ro unknown
- 2016-07-06 PT PT168219269T patent/PT3319612T/pt unknown
- 2016-07-06 SM SM20250264T patent/SMT202500264T1/it unknown
- 2016-07-06 CN CN201680050744.1A patent/CN108135911B/zh active Active
- 2016-07-06 HR HRP20211282TT patent/HRP20211282T1/hr unknown
- 2016-07-06 CN CN202110635348.8A patent/CN113501855A/zh active Pending
- 2016-07-06 DK DK20214736.9T patent/DK3812392T3/da active
- 2016-07-06 ES ES16821926T patent/ES2884086T3/es active Active
- 2016-07-06 AU AU2016289971A patent/AU2016289971C1/en active Active
- 2016-07-06 HR HRP20250799TT patent/HRP20250799T1/hr unknown
- 2016-07-06 MX MX2018000280A patent/MX382122B/es unknown
- 2016-07-06 RS RS20250662A patent/RS66996B1/sr unknown
2017
- 2017-12-24 IL IL256531A patent/IL256531B/en active IP Right Grant
2018
- 2018-01-05 PH PH12018500061A patent/PH12018500061A1/en unknown
- 2018-01-22 CO CONC2018/0000589A patent/CO2018000589A2/es unknown
2020
- 2020-12-24 JP JP2020215040A patent/JP2021046444A/ja not_active Withdrawn
2021
- 2021-08-06 US US17/396,034 patent/US11732000B2/en active Active
- 2021-08-13 CY CY20211100733T patent/CY1124620T1/el unknown
- 2021-08-20 AU AU2021218230A patent/AU2021218230B2/en active Active
2022
- 2022-06-03 JP JP2022091046A patent/JP7602512B2/ja active Active
2023
- 2023-06-29 US US18/216,057 patent/US20240132535A1/en active Pending
2024
- 2024-01-15 AU AU2024200254A patent/AU2024200254B2/en active Active
- 2024-12-06 JP JP2024213248A patent/JP2025026574A/ja active Pending

Also Published As

Publication number	Publication date
JP2022107795A (ja)	2022-07-22
PT3319612T (pt)	2021-08-24
CA2991313C (en)	2023-12-19
FI3812392T3 (fi)	2025-07-11
HRP20211282T1 (hr)	2021-11-12
RU2018104245A3 (2)	2019-10-31
EP3812392A1 (en)	2021-04-28
EP3319612A4 (en)	2019-03-06
MX2020010690A (es)	2022-02-25
CN108135911A (zh)	2018-06-08
LT3319612T (lt)	2021-08-25
MX2021005052A (es)	2022-10-11
DK3812392T3 (da)	2025-07-21
IL289976A (en)	2022-03-01
RU2018104245A (ru)	2019-08-07
CN118994288A (zh)	2024-11-22
AU2021218230A1 (en)	2021-09-09
EP4599887A2 (en)	2025-08-13
HUE071964T2 (hu)	2025-10-28
JP2021046444A (ja)	2021-03-25
EP3319612B1 (en)	2021-05-19
IL282048B2 (en)	2024-09-01
PE20180482A1 (es)	2018-03-07
RU2742333C2 (ru)	2021-02-04
MY197698A (en)	2023-07-06
ES2884086T3 (es)	2021-12-10
ES3036110T3 (en)	2025-09-12
PL3812392T3 (pl)	2025-09-08
US20240132535A1 (en)	2024-04-25
MD3319612T2 (ro)	2021-10-31
RU2021100377A (ru)	2021-05-18
US11117924B2 (en)	2021-09-14
PH12018500061A1 (en)	2018-07-23
CN113501855A (zh)	2021-10-15
US11732000B2 (en)	2023-08-22
PL3319612T3 (pl)	2021-12-20
IL282048A (en)	2021-05-31
HUE055199T2 (hu)	2021-11-29
IL256531A (en)	2018-02-28
EP4599887A8 (en)	2025-09-24
DK3319612T3 (da)	2021-08-23
SI3812392T1 (sl)	2025-09-30
HRP20250799T1 (hr)	2025-09-12
EP3812392B1 (en)	2025-04-16
US20180194797A1 (en)	2018-07-12
AU2021218230B2 (en)	2023-11-16
MA54851A (fr)	2021-12-08
SG10202002655VA (en)	2020-05-28
LT3812392T (lt)	2025-08-11
EP4599887A3 (en)	2025-10-15
MX390271B (es)	2025-03-20
IL256531B (en)	2021-04-29
JP2018519328A (ja)	2018-07-19
WO2017007840A1 (en)	2017-01-12
KR20240166589A (ko)	2024-11-26
MX382122B (es)	2025-03-13
PT3812392T (pt)	2025-07-21
CA2991313A1 (en)	2017-01-12
IL289976B2 (en)	2026-04-01
US20220048943A1 (en)	2022-02-17
IL282048B1 (en)	2024-05-01
CY1124620T1 (el)	2022-07-22
AU2016289971A1 (en)	2018-01-25
KR20180026742A (ko)	2018-03-13
CN108135911B (zh)	2021-06-25
BR112018000205A2 (pt)	2018-09-04
IL289976B1 (en)	2025-12-01
AU2016289971B2 (en)	2021-09-09
AU2024200254B2 (en)	2026-02-26
RS66996B1 (sr)	2025-08-29
CO2018000589A2 (es)	2018-07-10
NZ738849A (en)	2024-10-25
SMT202100476T1 (it)	2021-09-14
JP2025026574A (ja)	2025-02-21
EP3319612A1 (en)	2018-05-16
MX2018000280A (es)	2018-03-08
SMT202500264T1 (it)	2025-09-12
JP7602512B2 (ja)	2024-12-18
NZ777721A (en)	2024-10-25
PH12020551586A1 (en)	2023-07-31
AU2016289971C1 (en)	2022-12-08
SI3319612T1 (sl)	2021-11-30
AU2024200254A1 (en)	2024-02-01

Publication	Publication Date	Title
AU2024200254B2 (en)	2026-02-26	Oxysterols and methods of use thereof
EP3436022B1 (en)	2022-03-09	Oxysterols and methods of use thereof
RS61718B1 (sr)	2021-05-31	Oksisteroli i postupci za njihovu upotrebu
RU2850468C2 (ru)	2025-11-12	Оксистеролы и способы их применения
HK40051330B (en)	2025-11-14	Oxysterols and methods of use thereof
HK40051330A (en)	2022-01-07	Oxysterols and methods of use thereof
HK1247563B (en)	2022-01-28	Oxysterols and methods of use thereof
BR122021005567B1 (pt)	2024-03-26	Composto oxiesterol, composição farmacêutica e seus usos
BR112018000205B1 (pt)	2023-08-01	Composto oxiesterol, composição farmacêutica e seus usos
HK40004292B (en)	2022-12-16	Oxysterols and methods of use thereof
HK40004292A (en)	2020-04-24	Oxysterols and methods of use thereof
BR112018070123B1 (pt)	2024-08-20	Compostos oxiesteróis, composição farmacêutica compreendendo os referidos compostos e uso destes